title: Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.
abstract: OBJECTIVE
  To appraise multiple systematic reviews on the same clinical topic, focusing on predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores.
  
  
  METHODS
  Case study.
  
  
  METHODS
  Reviews providing at least individual quantitative estimates on role of acetylcysteine in the prevention of contrast associated nephropathy.
  
  
  METHODS
  PubMed, the database of abstracts of reviews of effects, and the Cochrane database of systematic reviews (updated March 2005).
  
  
  METHODS
  Funding, compliance with the QUOROM checklist, scores on the Oxman and Guyatt quality index, and authors' recommendations.
  
  
  RESULTS
  10 systematic reviews, published August 2003 to March 2005, were included. Nine pooled events despite heterogeneity and five recommended routine use of acetylcysteine, whereas the remaining studies called for further research. Compliance with the 18 items on the QUOROM checklist was relatively high (median 16, range 11 to 17), although shorter manuscripts had significantly lower scores (R = 0.73; P = 0.016). Reviewers who reported previous not for profit funding were more likely to score higher on the Oxman and Guyatt quality index. No association was found between QUOROM and Oxman and Guyatt scores (R = -0.06; P = 0.86), mainly because of greater emphasis of the Oxman and Guyatt scores on the appraisal of bias in selection and validity assessment (inadequate in five reviews).
  
  
  CONCLUSIONS
  Multiple systematic reviews on the same clinical topic varied in quality of reporting and recommendations. Longer manuscripts and previous not for profit funding were associated with higher quality.
authors.affiliation: Hemodynamics and Cardiovascular Radiology Service, Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Italy. gbiondizoccai@gmail.com
authors.forename: Giuseppe G L
authors.initials: GG
authors.lastname: Biondi-Zoccai
authors.forename: Marzia
authors.initials: M
authors.lastname: Lotrionte
authors.forename: Antonio
authors.initials: A
authors.lastname: Abbate
authors.forename: Luca
authors.initials: L
authors.lastname: Testa
authors.forename: Enrico
authors.initials: E
authors.lastname: Remigi
authors.forename: Francesco
authors.initials: F
authors.lastname: Burzotta
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Agostoni
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D003287:Contrast Media / Q000009:adverse effects*; D019983:Guideline Adherence; D006801:Humans; D018156:Journalism, Medical / Q000592:standards*; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D015201:Meta-Analysis as Topic; D011786:Quality Control; D016032:Randomized Controlled Trials as Topic; D012109:Research Support as Topic; D012196:Review Literature as Topic
chemical_list: D003287:Contrast Media; D000111:Acetylcysteine